Skip to main content

Table 1 Expression of ezrin, ezrin Thr-567 and ezrin Tyr-353 in NSCLC

From: Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer

  Ezrin EzrinThr-567 EzrinTyr-353
Diagnosis No. of cases Positive rate Strongly positive rate Positive rate Strongly positive rate Positive rate Strongly positive rate
   (+ ~ +++, %) (++ ~ +++, %) (+ ~ +++, %) (++ ~ +++, %) (+ ~ +++, %) (++ ~ +++, %)
NSCLC 150 94 (62.7%)** 61 (40.7%)** 95 (63.3%)** 68 (45.3%)** 107 (71.3%)** 72 (48.0%)**
Adjacent non-tumor 150 47 (31.3%) 5 (3.3%) 21 (14.0%) 7 (4.7%) 17 (11.3%) 2 (1.3%)
Normal lung tissues 14 5 (35.7%) 0 (0.0%) 2 (14.3%) 0 (0.0%) 1 (7.1%) 0 (0.0%)
  1. Positive rate: percentage of positive cases with ‘+’, ‘++’, and ‘+++’, Strongly positive rate: percentage of positive cases with ‘++’, and ‘+++’, **P < 0.01: NSCLC vs Adjacent non-tumor and Normal lung tissues.